Related Experiment Video
Updated: Jun 18, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
Case Report: Amiodarone-induced multi-organ toxicity
Jingrui Yan1, Yuanyuan Xu2, Qiang Zhu1
1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Frontiers in Cardiovascular Medicine
|August 1, 2024
Summary
Amiodarone effectively treats arrhythmias but can cause serious side effects like liver and thyroid issues. Early detection and management are crucial for patient safety during amiodarone therapy.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Amiodarone is a Class III antiarrhythmic medication frequently prescribed for ventricular arrhythmias and atrial fibrillation.
- Its established efficacy in managing cardiac rhythm disorders and improving survival rates, particularly in ventricular fibrillation, is well-documented.
Observation:
- A case study details a 73-year-old female patient experiencing gastrointestinal distress and dizziness while on amiodarone therapy.
- Despite prior normal health screenings, the patient developed abnormal liver and thyroid function tests, with imaging revealing lung and liver abnormalities indicative of amiodarone toxicity.
Findings:
- Switching the patient from amiodarone to sotalol resulted in symptom resolution and normalization of thyroid and liver function tests.
- Radiological evidence showed recovery from interstitial lung fibrosis and decreased liver density, supporting the diagnosis of amiodarone-induced toxicity.
Implications:
- Long-term amiodarone use necessitates vigilant monitoring for adverse effects, including thyroid dysfunction, hepatotoxicity, and pulmonary toxicity.
- Prompt recognition and management, potentially involving therapeutic adjustments, are vital for mitigating amiodarone-related risks and ensuring patient well-being.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K